Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men

被引:11
作者
Meikle, AW
Matthias, D
Hoffman, AR
机构
[1] Univ Utah, Sch Med, Dept Med, Div Endocrinol, Salt Lake City, UT 84108 USA
[2] ARUP Labs, Salt Lake City, UT USA
[3] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[4] VA Palo Alto Care Syst, Palo Alto, CA USA
[5] Stanford Univ, Palo Alto, CA 94304 USA
关键词
hypogonadism; testosterone; transdermal gel; pharmacokinetics;
D O I
10.1111/j.1464-410X.2003.04750.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To determine the regimen that would most effectively maintain serum testosterone concentrations in treated hypogonadal men within the normal reference range of 3-11.4 mug/L. PATIENTS AND METHODS Eighteen men aged 24-69 years with either primary or secondary hypogonadism participated in and 16 completed a randomized, six-treatment regimen, three-period (phase), three-way matrix-type crossover study. A 1% and 2% testosterone gel (CP601, Cellegy Pharmaceuticals, Inc., San Francisco, USA) was administered either once or twice daily transdermally at different body sites to determine optimal dosing, application sites, and its pharmacokinetics and tolerability in hypogonadal men. Treatments A-F included 1 g of 1% and 2% gel that was equivalent to 10 or 20 mg of testosterone, applied once or twice daily to the skin of either the thigh or the upper arm. Six men also participated in a study of 3 g of 2% gel that was equivalent to 60 mg of testosterone applied once daily, half on each thigh. Pharmacokinetic variables were calculated for testosterone for each man in each treatment period and the results analysed by ANOVA. RESULTS In general the higher dose regimens produced higher serum concentrations of testosterone; the 3 g/2% dose was most successful in maintaining serum testosterone within the normal reference range. The average testosterone concentration (C-avg) was 6.52 mug/L and all men had a C-avg of > 3.0 mug/L. The prediction of all men achieving a C-avg of > 3.0 mug/L was 96%. The mean minimum concentration (C-min) was 3.83 mug/L and half the patients had a C-min of > 3.0 mug/L. Most men had serum testosterone levels within the normal reference range throughout the 24 h, and the treatment was well tolerated. CONCLUSIONS The 3 g/2% dose applied to the skin daily resulted in serum testosterone in the normal reference range in most hypogonadal men. Dose adjustments to either a lower or higher dose should shift serum testosterone concentration to the desired range in those who do not achieve this range with this dose.
引用
收藏
页码:789 / 795
页数:7
相关论文
共 37 条
[1]   TRANSDERMAL TESTOSTERONE THERAPY IN THE TREATMENT OF MALE HYPOGONADISM [J].
AHMED, SR ;
BOUCHER, AE ;
MANNI, A ;
SANTEN, RJ ;
BARTHOLOMEW, M ;
DEMERS, LM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 66 (03) :546-551
[2]   Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Allen, RP ;
Sanders, SW ;
Mazer, NA .
JOURNAL OF UROLOGY, 1996, 155 (05) :1604-1608
[3]   Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Caramelli, KE ;
Rajaram, L ;
Sanders, SW ;
Mazer, NA .
CLINICAL ENDOCRINOLOGY, 1997, 47 (06) :727-737
[4]   A BIODEGRADABLE TESTOSTERONE MICROCAPSULE FORMULATION PROVIDES UNIFORM EUGONADAL LEVELS OF TESTOSTERONE FOR 10-11 WEEKS IN HYPOGONADAL MEN [J].
BHASIN, S ;
SWERDLOFF, RS ;
STEINER, B ;
PETERSON, MA ;
MERIDORES, T ;
GALMIRINI, M ;
PANDIAN, MR ;
GOLDBERG, R ;
BERMAN, N .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (01) :75-83
[5]   Testosterone replacement increases fat-free mass and muscle size in hypogonadal men [J].
Bhasin, S ;
Storer, TW ;
Berman, N ;
Yarasheski, KE ;
Clevenger, B ;
Phillips, J ;
Lee, WP ;
Bunnell, TJ ;
Casaburi, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :407-413
[6]   Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - A Clinical research center study [J].
Brodsky, IG ;
Balagopal, P ;
Nair, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3469-3475
[7]   CRITICAL EVALUATION OF THE POTENTIAL ERROR IN PHARMACOKINETIC STUDIES OF USING THE LINEAR TRAPEZOIDAL RULE METHOD FOR THE CALCULATION OF THE AREA UNDER THE PLASMA LEVEL TIME CURVE [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06) :539-546
[8]   TESTOSTERONE REPLACEMENT WITH TRANSDERMAL THERAPEUTIC SYSTEMS - PHYSIOLOGICAL SERUM TESTOSTERONE AND ELEVATED DIHYDROTESTOSTERONE LEVELS [J].
CUNNINGHAM, GR ;
CORDERO, E ;
THORNBY, JI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (17) :2525-2530
[9]   Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men [J].
Dobs, AS ;
Meikle, AW ;
Arver, S ;
Sanders, SW ;
Caramelli, KE ;
Mazer, NA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3469-3478
[10]   Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system [J].
Dobs, AS ;
Bachorik, PS ;
Arver, S ;
Meikle, AW ;
Sanders, SW ;
Caramelli, KE ;
Mazer, NA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1026-1033